Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Andy's Mind: A Co-created Serious Game for People With Psychosis (PSICOGAME) (PSICOGAME)

12 novembre 2026 mis à jour par: Fundació Sant Joan de Déu

Development and Evaluation of the Effectiveness of a Psychoeducational Serious Game for People With Schizophrenia Spectrum and Other Psychotic Disorders

The goal of this clinical trial is to learn whether Andy's Mind, a psychoeducational card game co-created with a person with lived experience of psychosis, improves illness awareness (insight) and attitudes toward treatment in adults with schizophrenia spectrum and other psychotic disorders, compared with conventional group psychoeducation.

The main questions it aims to answer are:

  • Does Andy's Mind improve insight into mental disorder more than conventional psychoeducation?
  • Does Andy's Mind improve attitudes toward medication, as an indicator of treatment adherence, more than conventional psychoeducation?

Researchers will also look at psychotic symptoms, attitudes toward alcohol and other drugs, and participant satisfaction.

Participants will:

  • Be randomly assigned to one of two groups: the Andy's Mind game group or a conventional psychoeducation group.
  • Attend 8 weekly group sessions of 45 minutes. Both groups cover the same topics: what psychosis is, symptoms, treatment, side effects, substance use and relapse prevention.
  • Complete interviews and questionnaires before the sessions, right after the last session, and two months later.

The study takes place in mental health services in Catalonia, Spain, including prison mental health units, psychosocial rehabilitation services and community mental health centers.

Aperçu de l'étude

Description détaillée

Background Poor insight and low adherence to antipsychotic treatment are common in people with psychotic disorders and are associated with relapse and rehospitalization. Group psychoeducation is an evidence-based intervention that improves illness awareness and adherence, but many patients have difficulty understanding and integrating the information delivered in conventional formats, particularly in settings with cognitive, language and cultural barriers such as prison mental health units. Serious games may increase intrinsic motivation, participation and peer interaction, and reduce the hierarchical structure of conventional psychoeducation. To date, no analog serious game for psychoeducation in psychosis has been evaluated in a randomized controlled trial.

Intervention development The study has two phases. In Phase 1, Andy's Mind was developed through participatory co-design with mental health professionals and a person with lived experience of psychosis, who also illustrated the cards, and was tested in a usability pilot in two prison mental health units (n=10). Phase 1 participants are not eligible for Phase 2. This registration corresponds to Phase 2, the randomized controlled trial.

Experimental intervention Andy's Mind is an analog card game for 2 to 6 players. It uses a science-fiction narrative in which psychotic symptoms are represented as creatures that players learn to stabilize using treatment and protective factors while facing relapse risks such as substance use or sleep deprivation. The final version includes 104 cards in seven categories (symptom, treatment, side effect, protection, attack/relapse, boom and wild cards), with images and text in Spanish, English and Arabic and high-contrast color coding. The intervention consists of 8 weekly group sessions of 45 minutes with 4 to 6 participants: sessions 1 and 2 introduce the rules and the meaning of each card, and sessions 3 to 8 consist of gameplay followed by 5 to 10 minutes of questions to check understanding. Sessions are led by mental health professionals trained by the research team using a facilitator manual.

Active comparator Conventional group psychoeducation based on the PIENSA program, with the same dose (8 weekly sessions of 45 minutes, groups of 4 to 8 participants) and the same content: what psychosis is (session 1), symptoms (sessions 2 and 3), treatments (session 4), side effects (session 5), drugs and psychosis (session 6), relapse prevention, protective and precipitating factors (session 7), and review (session 8).

Design and randomization Multicenter, two-arm, parallel-group, open-label randomized controlled trial. Eighty participants (40 per arm) are recruited by consecutive sampling. Allocation follows a randomization sequence generated by a person external to the research team and linked to the consecutive participant code. Assessments are carried out by members of the research team who do not deliver the interventions; assessors are not blinded to group allocation.

Assessments Participants are assessed at baseline (T0), immediately after the 8-session intervention (T1) and at a 2-month follow-up (T2). Cognitive screening with the SCIP-S is performed at baseline only, as an exclusion criterion. Sociodemographic and clinical data, including a descriptive substance use questionnaire, are collected at baseline. Questionnaires are completed on paper or directly in REDCap depending on device availability and unit regulations; paper data are transcribed into REDCap by the principal investigator.

Sample size and analysis With alpha 0.05 (one-sided) and 80% power, 80 participants allow detection of an effect size of Cohen's d = 0.63 in the between-group comparison at T1 using ANCOVA adjusted for baseline scores, assuming a pre-post correlation of 0.2. The main analysis follows the intention-to-treat principle and compares groups at T1 and T2 with ANCOVA adjusted for baseline values. Care setting (prison, community, rehabilitation) will be considered as a covariate. Change over time will also be explored with repeated-measures or linear mixed models including group, time and group-by-time interaction. A per-protocol analysis will be performed as a complementary analysis.

Type d'étude

Interventionnel

Inscription (Estimé)

80

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Andrea Fontán Abeijón, RN, BSc
  • Numéro de téléphone: +34687343637
  • E-mail: andrea.fontan@sjd.es

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Barcelona
      • Sant Boi de Llobregat, Barcelona, Espagne, 08830
        • Recrutement
        • Parc Sanitari Sant Joan de Déu
        • Contact:
          • Andrea Fontán Abeijón, RN, BSc
          • Numéro de téléphone: +34687343637
          • E-mail: andrea.fontan@sjd.es
        • Contact:
        • Chercheur principal:
          • Andrea Fontán Abeijón, RN, BSc

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 65 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Adults aged 18 to 65 years, inclusive.
  • Diagnosis within the schizophrenia spectrum and other psychotic disorders according to DSM-5: schizophrenia, schizoaffective disorder, delusional disorder, brief psychotic disorder, schizophreniform disorder, substance/medication-induced psychotic disorder, psychotic disorder due to another medical condition, or unspecified psychotic disorder.
  • Receiving care in a prison, community or rehabilitation mental health service.
  • Signed informed consent from the participant and, when applicable, from the legal guardian.

Exclusion Criteria:

  • Moderate or severe intellectual disability.
  • Cognitive impairment on the Screen for Cognitive Impairment in Psychiatry, Spanish version (SCIP-S), defined as a total score below the 5th percentile or any subscale score below the 3rd percentile according to clinical-sample norms adjusted for age and educational level.
  • Active psychotic episode.
  • Language barrier preventing completion of the assessments or participation in the group sessions.
  • Previous participation in the Phase 1 usability pilot of the study.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Andy's Mind serious game

Participants attend 8 weekly group sessions of 45 minutes (4 to 6 participants per group) using the Andy's Mind psychoeducational card game, led by trained mental health professionals.

Analog psychoeducational card game for 2 to 6 players, co-designed with mental health professionals and a person with lived experience of psychosis. Psychotic symptoms are represented as creatures that players stabilize using treatment and protective factors while facing relapse risks. 104 cards in seven categories (symptom, treatment, side effect, protection, attack/relapse, boom and wild cards), with text in Spanish, English and Arabic. Sessions 1-2: introduction to rules and cards. Sessions 3-8: gameplay followed by 5-10 minutes of questions to check understanding.

Comparateur actif: Conventional psychoeducation

Participants attend 8 weekly group sessions of 45 minutes (4 to 8 participants per group) of conventional psychoeducation based on the PIENSA program, covering the same topics as the experimental arm.

Structured group psychoeducation based on the PIENSA program. Session 1: what is psychosis. Sessions 2-3: symptoms. Session 4: treatments. Session 5: side effects. Session 6: drugs and psychosis. Session 7: relapse prevention, protective and precipitating factors. Session 8: review and questions.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Insight into mental disorder (Scale to Assess Unawareness of Mental Disorder, SUMD)
Délai: Baseline and immediately after the 8-week intervention

Insight assessed with the Spanish version of the SUMD, a clinician-rated semi-structured interview that evaluates awareness of having a mental disorder, awareness of the effects of medication and awareness of the social consequences of the disorder, plus awareness and attribution of 17 specific symptoms. Items are scored from 1 (aware) to 5 (unaware); higher scores indicate lower insight. Between-group comparison of post-intervention scores adjusted for baseline.

Baseline and immediately after the 8-week intervention
Attitudes toward antipsychotic medication as an indicator of treatment adherence (Drug Attitude Inventory, DAI-10)
Délai: Baseline and immediately after the 8-week intervention

Self-reported attitudes and beliefs about psychiatric medication assessed with the Spanish version of the 10-item Drug Attitude Inventory (DAI-10). Each item is scored +1 or -1; total score ranges from -10 to +10, with higher scores indicating more positive attitudes toward medication. Between-group comparison of post-intervention scores adjusted for baseline.

Baseline and immediately after the 8-week intervention

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Maintenance of insight (SUMD) at follow-up
Délai: Baseline and 2 months after the end of the intervention

SUMD scores as described for the primary outcome, compared between groups at 2-month follow-up adjusted for baseline. Higher scores indicate lower insight.

Baseline and 2 months after the end of the intervention
Maintenance of attitudes toward medication (DAI-10) at follow-up
Délai: Baseline and 2 months after the end of the intervention

DAI-10 total score (range -10 to +10; higher scores indicate more positive attitudes toward medication), compared between groups at 2-month follow-up adjusted for baseline.

Baseline and 2 months after the end of the intervention
Psychotic symptom severity (Positive and Negative Syndrome Scale, PANSS)
Délai: Baseline, immediately after the 8-week intervention, and 2 months after the end of the intervention

Clinician-rated severity of positive, negative and general psychopathology symptoms assessed with the 30-item PANSS. Each item is scored from 1 (absent) to 7 (extreme); total score ranges from 30 to 210, with higher scores indicating greater symptom severity. Total and subscale scores will be analyzed.

Baseline, immediately after the 8-week intervention, and 2 months after the end of the intervention
Attitudes toward alcohol (Escala de Actitudes hacia el Alcohol, ESACAL)
Délai: Baseline, immediately after the 8-week intervention, and 2 months after the end of the intervention

Self-reported attitudes toward alcohol assessed with the 13-item ESACAL, rated on a 5-point Likert scale (total score range 13 to 65). Items unfavorable to health are reverse-scored, so higher scores indicate attitudes more favorable to health.

Baseline, immediately after the 8-week intervention, and 2 months after the end of the intervention
Attitudes toward other drugs (Escala de Actitudes hacia otras Drogas, ESACDRO)
Délai: Baseline, immediately after the 8-week intervention, and 2 months after the end of the intervention

Self-reported attitudes toward drugs other than alcohol assessed with the 13-item ESACDRO, rated on a 5-point Likert scale (total score range 13 to 65). Items unfavorable to health are reverse-scored, so higher scores indicate attitudes more favorable to health.

Baseline, immediately after the 8-week intervention, and 2 months after the end of the intervention
Satisfaction and engagement with the intervention
Délai: Immediately after the 8-week intervention

Self-reported satisfaction and engagement with the intervention assessed with an ad hoc questionnaire rated on a 5-point Likert scale (1 to 5), with higher scores indicating greater satisfaction. Compared between groups.

Immediately after the 8-week intervention

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Andrea Fontán Abeijón, RN, BSc, Parc Sanitari Sant Joan de Déu

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

16 février 2026

Achèvement primaire (Estimé)

1 septembre 2027

Achèvement de l'étude (Estimé)

1 décembre 2027

Dates d'inscription aux études

Première soumission

12 novembre 2026

Première soumission répondant aux critères de contrôle qualité

12 novembre 2026

Première publication (Réel)

18 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

12 novembre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • PIC-29-23
  • PR-623/2023 (Autre subvention/numéro de financement: Col.legi Oficial d'Infermeres i Infermers de Barcelona (COIB))
  • P202311 (Autre subvention/numéro de financement: Parc Sanitari Sant Joan de Déu / Institut de Recerca Sant Joan de Déu)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

De-identified individual participant data underlying the results reported in publications (sociodemographic variables and SUMD, DAI-10, PANSS, ESACAL, ESACDRO and satisfaction scores) will be available upon reasonable request. Because the sample includes people in prison mental health settings, a vulnerable population, data will not be deposited in an open repository and will only be shared under a data sharing agreement, for purposes consistent with the informed consent.

Délai de partage IPD

Beginning 6 months after publication of the main results and for 5 years thereafter.

Critères d'accès au partage IPD

Researchers who provide a methodologically sound proposal approved by an ethics committee may request access by contacting the principal investigator. Access requires approval by the sponsor (Fundació per a la Recerca i la Docència Sant Joan de Déu) and the signing of a data sharing agreement in compliance with the EU General Data Protection Regulation.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner